CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Association of Chromosome Arm 9p Abnormalities With Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group
Nyla A. Heerema(The Ohio State University), Fatih M. Uckun(University of Southern California), Paul S. Gaynon(University of Southern California), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center), Wen Liu‐Mares(Children's Oncology Group), Raymond J. Hutchinson(Children's Hospital of Los Angeles), Diane C. Arthur(National Cancer Institute), James B. Nachman(University of Chicago), Harland N. Sather(Children's Oncology Group), Bruce Bostrom(Minnesota West Community & Technical College), Beverly J. Lange(Philadelphia University), Martha G. Sensel(Parker Hughes Cancer Center)
Unknown
January 1, 2016
Cited by 0
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825